GLP-1 Drugs Cut Heart Failure Hospitalizations by 27% in Patients with Preserved Ejection Fraction | Research

The takeaway

GLP-1 receptor agonists reduced the combined risk of death and heart failure hospitalization by 27% in HFpEF patients across 6 studies with 4,043 patients, with particularly strong benefits in those with atrial fibrillation.

27% reduction in death/hospitalization
GLP-1RAs reduced the composite outcome by 27% (HR 0.73) in HFpEF patients with zero heterogeneity across studies, filling a major treatment gap

What the researchers found

Across 6 studies (5 RCTs, 1 cohort; n=4,043), GLP-1RAs reduced the composite of all-cause mortality and HF hospitalization by 27% (HR 0.73; 95% CI: 0.60-0.90; I²=0%). HF hospitalizations alone were reduced by 43% (HR 0.57; 95% CI: 0.32-1.00). All-cause mortality alone was not significantly reduced (HR 0.81; 95% CI: 0.58-1.14). Subgroup analysis showed greater benefits in patients with atrial fibrillation. Five studies evaluated semaglutide and one tirzepatide. RCTs showed low risk of bias.

Why it matters

HFpEF affects roughly half of all heart failure patients and has been called 'the greatest unmet need in cardiovascular medicine.' Unlike heart failure with reduced ejection fraction, HFpEF has had almost no effective drug treatments — until recently. SGLT2 inhibitors showed the first breakthrough; now GLP-1RAs appear to offer a second therapeutic option. For the millions of HFpEF patients worldwide, this represents a significant expansion of treatment options.

How the study worked

Systematic review and meta-analysis of PubMed, Scopus, Embase, and Web of Science through December 2024. Six studies (5 RCTs, 1 cohort) comparing GLP-1RAs to placebo or other hypoglycemic agents in HFpEF patients were included. GRADE and Risk of Bias assessments evaluated evidence quality. Random-effects meta-analysis pooled hazard ratios with subgroup analyses by patient characteristics.

What this study cannot tell us

Only 6 studies with 4,043 patients — modest for a meta-analysis. Five of six studies used semaglutide, so this may represent a drug-specific rather than class effect. The mortality reduction (HR 0.81) did not reach significance, likely due to limited statistical power. The single cohort study introduces observational bias. The HF hospitalization confidence interval barely reached significance (upper bound 1.00). Follow-up durations varied across studies.

How to read the evidence

Based on 5 RCTs with low risk of bias and one cohort study, this meta-analysis provides moderate-quality evidence. The zero heterogeneity strengthens confidence, though the total patient count (4,043) is relatively small and mortality significance was not achieved.

When this study was published

Published in 2025 with literature through December 2024, this meta-analysis captures the emerging evidence for GLP-1RAs in HFpEF — a rapidly evolving area with more trials expected.

The bigger picture

GLP-1 receptor agonists continue to expand their cardiovascular footprint. They've proven beneficial in atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, and now HFpEF. The zero heterogeneity (I²=0%) across studies is remarkable and suggests a consistent class effect. The atrial fibrillation subgroup finding is particularly intriguing — AF is common in HFpEF and the intersection of these conditions represents a large patient population with unmet treatment needs.

Questions still open

Is the HFpEF benefit a class effect of all GLP-1RAs or specific to semaglutide?
Why do HFpEF patients with atrial fibrillation derive greater benefit from GLP-1RAs?
Would longer follow-up demonstrate a significant mortality reduction in addition to the hospitalization benefit?

Common questions

What is HFpEF and why is it hard to treat?

Heart failure with preserved ejection fraction (HFpEF) means the heart pumps normally but has become stiff and can't fill properly. It accounts for about half of all heart failure cases and is more common in older adults, women, and those with obesity and diabetes. Unlike other types of heart failure, very few medications have shown clear benefits — making the finding that GLP-1 drugs reduce hospitalizations by 27% particularly significant.

Should HFpEF patients ask about GLP-1 drugs?

If you have HFpEF along with diabetes or obesity, GLP-1 drugs like semaglutide may offer cardiovascular benefits beyond blood sugar and weight management. This meta-analysis shows a meaningful reduction in heart failure hospitalizations. However, GLP-1RAs are not yet specifically approved for HFpEF. Discuss with your cardiologist whether a GLP-1 drug might be appropriate as part of your overall treatment plan.

Read the original research

Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.

Clinical research in cardiology : official journal of the German Cardiac Society

View on PubMed ↗Publisher’s paper ↗

Citation

Gonzales-Uribe, Antony; Ruiz-Cortez, Renato; Collantes-Silva, Nicole; Olivero, Lorenzo; Agarwal, Raksheeth; Arambulo-Castillo, Sebastian; Garcia-Geng, Alonso; Lyu, Xiajie; Mendoza-Quispe, Daniel; Becerra-Gonzales, Victor; Butrous, Hoda. (2025). Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.. Clinical research in cardiology : official journal of the German Cardiac Society. https://doi.org/10.1007/s00392-025-02710-8